Yahoo Canada Web Search

Search results

  1. Avalon’s long-standing and successful focus has been on seed and early stage companies, including many it formed in the life science and information technology sectors. We believe this is the most challenging and rewarding period of company creation – we are former entrepreneurs driven by passionate people pursuing disruptive ideas in ever changing market environments.

    • Contact

      Cambridge, Massachusetts 1770 Massachusetts Avenue, #708...

    • Rich Levandov

      Rich Levandov has over 25 years of experience as an...

    • Steve Tomlin

      He joined Avalon in 2001 and concentrates on wireless, IT,...

    • Jay Lichter, Ph.D

      Prior to joining Avalon as a Member of Avalon VIII, Dr....

  2. Kevin Kinsella is the founder of Avalon Ventures. He has specialized in the formation, financing and development of more than 125 early-stage companies, including: Athena Neurosciences Onyx Pharmaceuticals, Inc. [ONXX]; Sequana, Vertex Pharmaceuticals [VRTX], Synaptics [SYNA], Vocera Communications [VCRA], Amira Pharmaceuticals (acquired by BMS), AnaptysBio, JNANA and Eikonizo.

  3. Founded in 1983, Avalon Ventures is a venture capital firm headquartered in San Diego, California with a regional office in Cambridge, Massachusetts. The firm seeks to invest in early-stage companies in the information technology and life sciences sectors. This firm is a Registered Investment Adviser (RIA).

  4. replica rolex. All Content © 2024 Avalon Ventures, LLC.

  5. Avalon Ventures is an American venture capital firm that has founded and/or funded more than 127 information technology and life sciences companies. Created in 1983 by Kevin Kinsella, the company has offices in La Jolla, California and Cambridge, Massachusetts.

  6. Dec 6, 2022 · Avalon Ventures formed in 1983 and raised about $750 million through 11 funds, according to the firm. Over the years, Avalon Ventures, as a technology and life-sciences investor, ...

  7. People also ask

  8. Dec 6, 2022 · Avalon Ventures is decoupling its life sciences investment operations from other tech investments to create Avalon BioVentures, a pure-play biotech firm with a new $135 million fund and an incubator in San Diego. Managing Partner Jay Lichter told BioCentury the firm’s LPs wanted more flexibility to allocate cash to the life sciences and ...

  1. People also search for